MetaCap

Nurix Therapeutics Inc. (NRIX)

NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

12.85-0.755 (-5.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NRIX stock chart

Technical analysis

Key statistics

All statistics
52-week range
12.83 – 28.23
Day range
12.83 – 13.67
Volume / Avg
2.43M / 2.47M
Beta
—

52-week range

$12.83$28.23

NRIX stock today

On Nov 20, NRIX ended the session at $12.85, shedding $0.755 (5.55%), versus the S&P 500's 3.70% decline. Shares are 54.5% below their 52-week high of $28.23, set on Aug 19, 2026 and 0.2% above the 52-week low of $12.83, near the bottom of the past year's range. NRIX is down 32.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.3%.

At 5.3x trailing earnings, Nurix Therapeutics trades below the peer-group median of 10.4x.

Summary generated from market data by MetaCap's automated system. Methodology

About Nurix Therapeutics

Company profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Headquarters
Brisbane, CA
Employees
317
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Nurix Therapeutics generated $84.0 million in revenue, up 54.0% from fiscal 2024. Nurix Therapeutics reported a net loss of $264.5 million, compared with a loss of $193.6 million a year earlier. Operating margin was -340.2%.

Nurix Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$83.98M$54.55M$76.99M$38.63M$29.75M
Growth+53.95%-29.15%+99.31%+29.84%+66.95%
Net income$-264.46M$-193.57M$-143.95M$-180.36M$-117.19M
EPS (diluted)$-3.05$-2.88$-2.65$-3.71$-2.73

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$33.50+160.80%

  • Strong buy 5
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $20.00High $41.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Aug/2026)
Oct 12, 2026
EPS actual vs est.
$4.73 vs $-0.56
Surprise
+944.64%

NRIX news

All NRIX news

Nurix Therapeutics peers

Health Care sector
NRIX peer companies
CompanyPrice% ChgMarket capCompare
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs NRIX
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs NRIX
ADRXADARx Pharmaceuticals Inc.12.79-9.68%$1.42Bvs NRIX
SRPTSarepta Therapeutics Inc.13.33-5.93%$1.43Bvs NRIX
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs NRIX
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs NRIX
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs NRIX
QUREuniQure N.V.19.35-4.35%$1.36Bvs NRIX

Indexes, lists and sector

Nurix Therapeutics stock FAQ

What is Nurix Therapeutics's stock price today?

NRIX last traded at $12.85 as of Nov 20, 4:00 PM EST, down 5.55% on the day. Prices are delayed at least 15 minutes.

What is NRIX's P/E ratio?

NRIX trades at a trailing P/E ratio of 5.29, compared with a median of 10.4 for its closest peers.

Who is Nurix Therapeutics's CEO?

Dr. Arthur T. Sands M.D., Ph.D. is the chief executive officer of Nurix Therapeutics Inc., which has about 317 employees.

What is the NRIX 52-week high?

The 52-week high for NRIX is $28.23 and the 52-week low is $12.83. The stock is currently 54.5% below its high.

Compare NRIX